OMC
ACRS icon

Old Mission Capital’s Aclaris Therapeutics ACRS Stock Holding History

Old Mission Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,663
Closed -$228K – 1338
2021
Q4 		$228K Buy
+15,663
New +$237K 0.01% 824
2021
Q3 		– Sell
-37,334
Closed -$656K – 953
2021
Q2 		$656K Buy
+37,334
New +$848K 0.02% 562
2020
Q3 		– Sell
-94,800
Closed -$154K – 418
2020
Q2 		$154K Buy
+94,800
New +$127K 0.01% 402

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Old Mission Capital's ACRS Position: Q1 2022 in Review

Old Mission Capital sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 15,663 shares — an estimated $228K sold.

Old Mission Capital first reported a position in ACRS in Q2 2020 and held it in 3 quarters. The position peaked at $656K in Q2 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Old Mission Capital reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Old Mission Capital sold 15,663 Aclaris Therapeutics shares in Q1 2022, an estimated $228K.
  • Old Mission Capital first reported a position in Aclaris Therapeutics in Q2 2020 and held it in 3 quarters.
  • Old Mission Capital's Aclaris Therapeutics position peaked at $656K in Q2 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Old Mission Capital's 13F filing for Q1 2022, filed 13 May 2022.